Literature DB >> 28475809

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013.

Quinn T Ostrom1,2, Haley Gittleman1,2, Jordan Xu3, Courtney Kromer4, Yingli Wolinsky1,2, Carol Kruchko5, Jill S Barnholtz-Sloan1,2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 28475809     DOI： 10.1093/neuonc/now207

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  383 in total

1.  Distinguishing Extravascular from Intravascular Ferumoxytol Pools within the Brain: Proof of Concept in Patients with Treated Glioblastoma.

Authors:  R F Barajas; D Schwartz; H L McConnell; C N Kersch; X Li; B E Hamilton; J Starkey; D R Pettersson; J P Nickerson; J M Pollock; R F Fu; A Horvath; L Szidonya; C G Varallyay; J J Jaboin; A M Raslan; A Dogan; J S Cetas; J Ciporen; S J Han; P Ambady; L L Muldoon; R Woltjer; W D Rooney; E A Neuwelt
Journal:  AJNR Am J Neuroradiol       Date:  2020-06-11       Impact factor: 3.825

Review 2.  Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.

Authors:  Priscilla K Brastianos; Franziska Maria Ippen; Umbreen Hafeez; Hui K Gan
Journal:  Oncologist       Date:  2018-04-27

3.  Meningiomas: skull base versus non-skull base.

Authors:  Torstein R Meling; Michele Da Broi; David Scheie; Eirik Helseth
Journal:  Neurosurg Rev       Date:  2018-04-07       Impact factor: 3.042

4.  Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.

Authors:  Francesco Pepe; Pasquale Pisapia; Maria Laura Del Basso de Caro; Floriana Conticelli; Umberto Malapelle; Giancarlo Troncone; Juan Carlos Martinez
Journal:  Histol Histopathol       Date:  2019-12-24       Impact factor: 2.303

5.  Diffusion Profiling via a Histogram Approach Distinguishes Low-grade from High-grade Meningiomas, Can Reflect the Respective Proliferative Potential and Progesterone Receptor Status.

Authors:  Georg Alexander Gihr; Diana Horvath-Rizea; Nikita Garnov; Patricia Kohlhof-Meinecke; Oliver Ganslandt; Hans Henkes; Hans Jonas Meyer; Karl-Titus Hoffmann; Alexey Surov; Stefan Schob
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

6.  Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts.

Authors:  Jorge A Benitez; Ciro Zanca; Jianhui Ma; Webster K Cavenee; Frank B Furnari
Journal:  J Vis Exp       Date:  2018-04-26       Impact factor: 1.355

7.  Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.

Authors:  Jinquan Cai; Qun Chen; Yuqiong Cui; Jiawei Dong; Meng Chen; Pengfei Wu; Chuanlu Jiang
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

8.  Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.

Authors:  Rimas V Lukas; Jordi Rodon; Kevin Becker; Eric T Wong; Kent Shih; Mehdi Touat; Marcella Fassò; Stuart Osborne; Luciana Molinero; Carol O'Hear; William Grossman; Joachim Baehring
Journal:  J Neurooncol       Date:  2018-08-02       Impact factor: 4.130

9.  Upregulated Expression of CUX1 Correlates with Poor Prognosis in Glioma Patients: a Bioinformatic Analysis.

Authors:  Xiujie Wu; Fan Feng; Chuanchao Yang; Moxuan Zhang; Yanhao Cheng; Yayun Zhao; Yayu Wang; Fengyuan Che; Jian Zhang; Xueyuan Heng
Journal:  J Mol Neurosci       Date:  2019-08-03       Impact factor: 3.444

Review 10.  Re-induction chemotherapy regimens in patients with recurrent central nervous system mixed malignant germ cell tumors.

Authors:  Mohammad H Abu Arja; Joseph R Stanek; Jonathan L Finlay; Mohamed S AbdelBaki
Journal:  Childs Nerv Syst       Date:  2018-08-03       Impact factor: 1.475
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.